Get started
ABBVIE INC. DL-,01ABBVIE INC. DL-,01ABBVIE INC. DL-,01

ABBVIE INC. DL-,01

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

4AB chart


Full chart

Key facts today


Berenberg has raised its price target for AbbVie Inc (ABBV) to $195 from $165, citing increased sales expectations for its immunology drugs while maintaining a 'Hold' rating.
AbbVie is recognized as a strong option for dividend investors, with nearly 70% of analysts rating the stock as a Buy and projecting earnings growth of 20% by 2025.
Analyze the impactAnalyze the impact

4AB upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪345.60 B‬ EUR
Dividend yield (indicated)
3.07%
Price to earnings Ratio (TTM)
88.90
Basic EPS (TTM)
2.32 EUR
Net income (FY)
‪4.09 B‬ EUR
Revenue (FY)
‪54.42 B‬ EUR
Shares float
‪1.76 B‬
Beta (1Y)
−0.01

Employees


Employees (FY)
‪55 K‬
Change (1Y)
‪+5 K‬ +10.00%
Revenue / Employee (1Y)
‪989.41 K‬ EUR
Net income / Employee (1Y)
‪74.43 K‬ EUR

About AbbVie Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Robert A. Michael
Website
abbvie.com
Headquarters
North Chicago
Founded
2011
FIGI
BBG003Q17NP7
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

4AB news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

4AB highest yielding bonds


A
ACT4218879
Allergan Funding SCS 3.8% 15-MAR-2025
Yield to maturity
73.69%
Maturity date
Mar 15, 2025
A
ACT4218883
Allergan Funding SCS 4.75% 15-MAR-2045
Yield to maturity
8.14%
Maturity date
Mar 15, 2045
A
ACT4176286
Allergan Funding SCS 4.85% 15-JUN-2044
Yield to maturity
7.69%
Maturity date
Jun 15, 2044
ABBV5083839
AbbVie Inc. 3.8% 15-MAR-2025
Yield to maturity
7.57%
Maturity date
Mar 15, 2025
A
ACT3910526
Actavis, Inc. 4.625% 01-OCT-2042
Yield to maturity
7.23%
Maturity date
Oct 1, 2042
A
ACT4218882
Allergan Funding SCS 4.55% 15-MAR-2035
Yield to maturity
6.31%
Maturity date
Mar 15, 2035
ABBV5068387
AbbVie Inc. 4.25% 21-NOV-2049
Yield to maturity
6.03%
Maturity date
Nov 21, 2049
US287YAW9
ABBVIE 16/46
Yield to maturity
5.92%
Maturity date
May 14, 2046
4ABB
ABBVIE 15/45
Yield to maturity
5.84%
Maturity date
May 14, 2045
ABBV4036937
AbbVie Inc. 4.4% 06-NOV-2042
Yield to maturity
5.77%
Maturity date
Nov 6, 2042
ABBV4693583
AbbVie Inc. 4.875% 14-NOV-2048
Yield to maturity
5.77%
Maturity date
Nov 14, 2048

See all 4AB bonds 

Sparks


Curated watchlists where 4AB is featured.

See all sparks 



Frequently Asked Questions


The current price of 4AB is 196.48 EUR — it has decreased by −0.95% in the past 24 hours. Watch ABBVIE INC. DL-,01 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange ABBVIE INC. DL-,01 stocks are traded under the ticker 4AB.
4AB stock has fallen by −0.93% compared to the previous week, the month change is a 5.24% rise, over the last year ABBVIE INC. DL-,01 has showed a 19.22% increase.
We've gathered analysts' opinions on ABBVIE INC. DL-,01 future price: according to them, 4AB price has a max estimate of 231.68 EUR and a min estimate of 159.68 EUR. Watch 4AB chart and read a more detailed ABBVIE INC. DL-,01 stock forecast: see what analysts think of ABBVIE INC. DL-,01 and suggest that you do with its stocks.
4AB reached its all-time high on Mar 4, 2025 with the price of 203.06 EUR, and its all-time low was 24.86 EUR and was reached on Jan 14, 2013. View more price dynamics on 4AB chart.
See other stocks reaching their highest and lowest prices.
4AB stock is 1.58% volatile and has beta coefficient of −0.01. Track ABBVIE INC. DL-,01 stock price on the chart and check out the list of the most volatile stocks — is ABBVIE INC. DL-,01 there?
Today ABBVIE INC. DL-,01 has the market capitalization of ‪343.90 B‬, it has decreased by −0.18% over the last week.
Yes, you can track ABBVIE INC. DL-,01 financials in yearly and quarterly reports right on TradingView.
ABBVIE INC. DL-,01 is going to release the next earnings report on Apr 25, 2025. Keep track of upcoming events with our Earnings Calendar.
4AB earnings for the last quarter are 2.09 EUR per share, whereas the estimation was 2.04 EUR resulting in a 2.12% surprise. The estimated earnings for the next quarter are 2.31 EUR per share. See more details about ABBVIE INC. DL-,01 earnings.
ABBVIE INC. DL-,01 revenue for the last quarter amounts to ‪14.59 B‬ EUR, despite the estimated figure of ‪14.33 B‬ EUR. In the next quarter, revenue is expected to reach ‪11.89 B‬ EUR.
4AB net income for the last quarter is ‪−30.91 M‬ EUR, while the quarter before that showed ‪1.39 B‬ EUR of net income which accounts for −102.22% change. Track more ABBVIE INC. DL-,01 financial stats to get the full picture.
Yes, 4AB dividends are paid quarterly. The last dividend per share was 1.59 EUR. As of today, Dividend Yield (TTM)% is 2.97%. Tracking ABBVIE INC. DL-,01 dividends might help you take more informed decisions.
ABBVIE INC. DL-,01 dividend yield was 3.54% in 2024, and payout ratio reached 263.15%. The year before the numbers were 3.87% and 220.33% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Mar 13, 2025, the company has ‪55.00 K‬ employees. See our rating of the largest employees — is ABBVIE INC. DL-,01 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ABBVIE INC. DL-,01 EBITDA is ‪19.80 B‬ EUR, and current EBITDA margin is 44.40%. See more stats in ABBVIE INC. DL-,01 financial statements.
Like other stocks, 4AB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ABBVIE INC. DL-,01 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ABBVIE INC. DL-,01 technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ABBVIE INC. DL-,01 stock shows the strong buy signal. See more of ABBVIE INC. DL-,01 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.